Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells

Sandeep S. Negi, Patrick A Brown

Research output: Contribution to journalArticle

Abstract

Enhanced rRNA synthesis is a downstream effect of many of the signaling pathways that are aberrantly activated in cancer, such as the PI3K/mTOR and MAP kinase pathways. Recently, two new rRNA synthesis inhibitors have demonstrated therapeutic effects on cancer cells while sparing normal cells. One of them, CX-5461, is currently in phase 1 clinical trials for hematological malignancies. Here, we investigate the effectiveness of transient treatment with this drug on acute lymphoblastic leukemia cells. Our results show that short exposure to CX-5461 followed by drug washout is sufficient to induce persistent G2 cell-cycle arrest and irreversible commitment to cell death, in spite of rRNA synthesis returning to normal within 24 hours of drug washout. The magnitude of cell death after transient exposure is similar to continuous exposure, but the time to cell death is relatively delayed with transient exposure. In this report, we also investigate rational drug combinations that can potentiate the effect of continuous CX-5461 treatment. We show that the checkpoint abrogator UCN-01 can relieve CX-5461-induced G2 arrest and potentiate the cytotoxic effects of CX-5461. Finally, we show that ERK1/2 is activated upon CX-5461 treatment, and that pharmacological inhibition of MEK1/2 leads to enhanced cell death in combination with CX-5461. In summary, our results provide enhanced effectiveness of CX-5461 in combination with other targeted agents.

Original languageEnglish (US)
Pages (from-to)34846-34858
Number of pages13
JournalOncotarget
Volume6
Issue number33
DOIs
StatePublished - 2015

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cell Death
Growth
Pharmaceutical Preparations
G2 Phase Cell Cycle Checkpoints
Clinical Trials, Phase I
CX 5461
Therapeutic Uses
Hematologic Neoplasms
Drug Combinations
Phosphatidylinositol 3-Kinases
Neoplasms
Phosphotransferases
Pharmacology

Keywords

  • Acute lymphoblastic leukemia
  • CX-5461
  • MAP kinase
  • RRNA synthesis
  • UCN-01

ASJC Scopus subject areas

  • Oncology

Cite this

Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells. / Negi, Sandeep S.; Brown, Patrick A.

In: Oncotarget, Vol. 6, No. 33, 2015, p. 34846-34858.

Research output: Contribution to journalArticle

@article{0e779539ab2f46d596d3db5b2c91eb9d,
title = "Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells",
abstract = "Enhanced rRNA synthesis is a downstream effect of many of the signaling pathways that are aberrantly activated in cancer, such as the PI3K/mTOR and MAP kinase pathways. Recently, two new rRNA synthesis inhibitors have demonstrated therapeutic effects on cancer cells while sparing normal cells. One of them, CX-5461, is currently in phase 1 clinical trials for hematological malignancies. Here, we investigate the effectiveness of transient treatment with this drug on acute lymphoblastic leukemia cells. Our results show that short exposure to CX-5461 followed by drug washout is sufficient to induce persistent G2 cell-cycle arrest and irreversible commitment to cell death, in spite of rRNA synthesis returning to normal within 24 hours of drug washout. The magnitude of cell death after transient exposure is similar to continuous exposure, but the time to cell death is relatively delayed with transient exposure. In this report, we also investigate rational drug combinations that can potentiate the effect of continuous CX-5461 treatment. We show that the checkpoint abrogator UCN-01 can relieve CX-5461-induced G2 arrest and potentiate the cytotoxic effects of CX-5461. Finally, we show that ERK1/2 is activated upon CX-5461 treatment, and that pharmacological inhibition of MEK1/2 leads to enhanced cell death in combination with CX-5461. In summary, our results provide enhanced effectiveness of CX-5461 in combination with other targeted agents.",
keywords = "Acute lymphoblastic leukemia, CX-5461, MAP kinase, RRNA synthesis, UCN-01",
author = "Negi, {Sandeep S.} and Brown, {Patrick A}",
year = "2015",
doi = "10.18632/oncotarget.5413",
language = "English (US)",
volume = "6",
pages = "34846--34858",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "33",

}

TY - JOUR

T1 - Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells

AU - Negi, Sandeep S.

AU - Brown, Patrick A

PY - 2015

Y1 - 2015

N2 - Enhanced rRNA synthesis is a downstream effect of many of the signaling pathways that are aberrantly activated in cancer, such as the PI3K/mTOR and MAP kinase pathways. Recently, two new rRNA synthesis inhibitors have demonstrated therapeutic effects on cancer cells while sparing normal cells. One of them, CX-5461, is currently in phase 1 clinical trials for hematological malignancies. Here, we investigate the effectiveness of transient treatment with this drug on acute lymphoblastic leukemia cells. Our results show that short exposure to CX-5461 followed by drug washout is sufficient to induce persistent G2 cell-cycle arrest and irreversible commitment to cell death, in spite of rRNA synthesis returning to normal within 24 hours of drug washout. The magnitude of cell death after transient exposure is similar to continuous exposure, but the time to cell death is relatively delayed with transient exposure. In this report, we also investigate rational drug combinations that can potentiate the effect of continuous CX-5461 treatment. We show that the checkpoint abrogator UCN-01 can relieve CX-5461-induced G2 arrest and potentiate the cytotoxic effects of CX-5461. Finally, we show that ERK1/2 is activated upon CX-5461 treatment, and that pharmacological inhibition of MEK1/2 leads to enhanced cell death in combination with CX-5461. In summary, our results provide enhanced effectiveness of CX-5461 in combination with other targeted agents.

AB - Enhanced rRNA synthesis is a downstream effect of many of the signaling pathways that are aberrantly activated in cancer, such as the PI3K/mTOR and MAP kinase pathways. Recently, two new rRNA synthesis inhibitors have demonstrated therapeutic effects on cancer cells while sparing normal cells. One of them, CX-5461, is currently in phase 1 clinical trials for hematological malignancies. Here, we investigate the effectiveness of transient treatment with this drug on acute lymphoblastic leukemia cells. Our results show that short exposure to CX-5461 followed by drug washout is sufficient to induce persistent G2 cell-cycle arrest and irreversible commitment to cell death, in spite of rRNA synthesis returning to normal within 24 hours of drug washout. The magnitude of cell death after transient exposure is similar to continuous exposure, but the time to cell death is relatively delayed with transient exposure. In this report, we also investigate rational drug combinations that can potentiate the effect of continuous CX-5461 treatment. We show that the checkpoint abrogator UCN-01 can relieve CX-5461-induced G2 arrest and potentiate the cytotoxic effects of CX-5461. Finally, we show that ERK1/2 is activated upon CX-5461 treatment, and that pharmacological inhibition of MEK1/2 leads to enhanced cell death in combination with CX-5461. In summary, our results provide enhanced effectiveness of CX-5461 in combination with other targeted agents.

KW - Acute lymphoblastic leukemia

KW - CX-5461

KW - MAP kinase

KW - RRNA synthesis

KW - UCN-01

UR - http://www.scopus.com/inward/record.url?scp=84946560980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946560980&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5413

DO - 10.18632/oncotarget.5413

M3 - Article

C2 - 26472108

AN - SCOPUS:84946560980

VL - 6

SP - 34846

EP - 34858

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 33

ER -